<div class="tables frame-topbot rowsep-0 colsep-0" id="tbl1">
<div class="captions"><span id="cecap50"><p id="spara90"><span class="label">Table 1</span>. Baseline characteristics</p></span></div>
<div class="groups"><table>
<thead><tr class="valign-top rowsep-1">
<th scope="col"></th>
<th scope="col"></th>
<th scope="col" class="align-left"><strong>Dulaglutide 1·5 mg (n=192)</strong></th>
<th scope="col" class="align-left"><strong>Dulaglutide 0·75 mg (n=190)</strong></th>
<th scope="col" class="align-left"><strong>Insulin glargine (n=194)</strong></th>
</tr></thead>
<tbody>
<tr class="valign-top">
<td class="align-left" colspan="2">Sex (women, men)</td>
<td class="align-left">88 (46%), 104 (54%)</td>
<td class="align-left">86 (45%), 104 (55%)</td>
<td class="align-left">101 (52%), 93 (48%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Age (years)</td>
<td class="align-left">64·7 (8·8)</td>
<td class="align-left">64·7 (8·6)</td>
<td class="align-left">64·3 (8·4)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Duration of diabetes (years)</td>
<td class="align-left">17·6 (8·7)</td>
<td class="align-left">18·0 (8·8)</td>
<td class="align-left">18·7 (8·7)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Race or ethnic origin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Hispanic or Latino</td>
<td class="align-left">78 (41%)</td>
<td class="align-left">75 (39%)</td>
<td class="align-left">79 (41%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Native American or Alaskan Native</td>
<td class="align-left">12 (6%)</td>
<td class="align-left">17 (9%)</td>
<td class="align-left">18 (9%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Asian</td>
<td class="align-left">7 (4%)</td>
<td class="align-left">4 (2%)</td>
<td class="align-left">5 (3%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Black or African American</td>
<td class="align-left">26 (14%)</td>
<td class="align-left">36 (19%)</td>
<td class="align-left">26 (14%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Native Hawaiian or other Pacific Islander</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">1 (1%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">White</td>
<td class="align-left">134 (71%)</td>
<td class="align-left">122 (66%)</td>
<td class="align-left">137 (71%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Multiple</td>
<td class="align-left">10 (5%)</td>
<td class="align-left">7 (4%)</td>
<td class="align-left">6 (3%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">HbA<sub>1c</sub> (%)</td>
<td class="align-left">8·6 (0·9)</td>
<td class="align-left">8·6 (1·1)</td>
<td class="align-left">8·6 (1·0)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">HBA<sub>1c</sub> (mmol/mol [SE])</td>
<td class="align-left">70·5 (9·3)</td>
<td class="align-left">70·3 (12·0)</td>
<td class="align-left">70·1 (10·6)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">HbA<sub>1c</sub> &gt;8·5%</td>
<td class="align-left">96 (50%)</td>
<td class="align-left">91 (48%)</td>
<td class="align-left">81 (42%)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Weight (kg)</td>
<td class="align-left">88·1 (16·0)</td>
<td class="align-left">90·9 (18·3)</td>
<td class="align-left">88·2 (18·5)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">BMI (kg/m<sup>2</sup>)</td>
<td class="align-left">32·1 (4·8)</td>
<td class="align-left">33·0 (5·5)</td>
<td class="align-left">32·4 (5·3)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Sitting systolic blood pressure (mm Hg)</td>
<td class="align-left">136·8 (13·7)</td>
<td class="align-left">137·4 (14·9)</td>
<td class="align-left">136·7 (14·3)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Sitting diastolic blood pressure (mm Hg)</td>
<td class="align-left">75·1 (9·1)</td>
<td class="align-left">74·6 (9·5)</td>
<td class="align-left">74·1 (9·0)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">Total daily insulin dose (U/day)</td>
<td class="align-left">58·8 (30·1)</td>
<td class="align-left">56·6 (31·2)</td>
<td class="align-left">59·3 (34·2)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">Duration of chronic kidney disease<a name="btbl1fn1" href="#tbl1fn1" class="workspace-trigger"><sup>*</sup></a> (years)</td>
<td class="align-left">4·2 (5·6)</td>
<td class="align-left">4·0 (4·9)</td>
<td class="align-left">3·5 (4·0)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">eGFR by creatinine (mL/min per 1·73 m<sup>2</sup>)</td>
<td class="align-left">38·1 (13·2)</td>
<td class="align-left">38·3 (12·3)</td>
<td class="align-left">38·5 (13·0)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">eGFR by creatinine (mL/min per 1·73 m<sup>2</sup>, geometric mean [SE])</td>
<td class="align-left">35·7 (1·0)</td>
<td class="align-left">36·2 (0·9)</td>
<td class="align-left">36·1 (0·9)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Baseline eGFR ≥60 to &lt;90</td>
<td class="align-left">9 (5%)</td>
<td class="align-left">7 (4%)</td>
<td class="align-left">14 (7%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Baseline eGFR ≥45 to &lt;60</td>
<td class="align-left">53 (28%)</td>
<td class="align-left">53 (28%)</td>
<td class="align-left">51 (26%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Baseline eGFR ≥30 to &lt;45</td>
<td class="align-left">73 (38%)</td>
<td class="align-left">75 (39%)</td>
<td class="align-left">67 (35%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Baseline eGFR ≥15 to &lt;30</td>
<td class="align-left">55 (29%)</td>
<td class="align-left">55 (29%)</td>
<td class="align-left">61 (31%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Baseline eGFR &lt;15</td>
<td class="align-left">2 (1%)</td>
<td class="align-left">0 (0%)</td>
<td class="align-left">1 (1%)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">eGFR by cystatin C (mL/min per 1·73m<sup>2</sup>, mean [SE])</td>
<td class="align-left">37·3 (14·2)</td>
<td class="align-left">37·7 (13·7)</td>
<td class="align-left">38·3 (14·8)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">eGFR by cystatin C (mL/min per 1·73m<sup>2</sup>, geometric mean [SE])</td>
<td class="align-left">34·8 (1·0)</td>
<td class="align-left">35·4 (0·9)</td>
<td class="align-left">35·6 (1·0)</td>
</tr>
<tr class="valign-top">
<td class="align-left" colspan="2">UACR (mg/g, median [IQR])</td>
<td class="align-left">213·7 (45·8–868·0)</td>
<td class="align-left">233·6 (36·7–946·5)</td>
<td class="align-left">195·6 (30·1–1015·1)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Normal albuminuria (UACR &lt;30)</td>
<td class="align-left">34 (18%)</td>
<td class="align-left">44 (23%)</td>
<td class="align-left">48 (25%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Microalbuminuria (UACR 30–300)</td>
<td class="align-left">74 (39%)</td>
<td class="align-left">61 (32%)</td>
<td class="align-left">56 (29%)</td>
</tr>
<tr class="valign-top">
<td></td>
<td class="align-left">Macroalbuminuria (UACR &gt;300)</td>
<td class="align-left">84 (44%)</td>
<td class="align-left">84 (44%)</td>
<td class="align-left">90 (46%)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left" colspan="2">Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use (mITT population)</td>
<td class="align-left">165 (90%)</td>
<td class="align-left">170 (94%)</td>
<td class="align-left">174 (94%)</td>
</tr>
</tbody>
</table></div>
<p class="legend"></p>
<p id="spara100">Data
 are mean (SD) or n (%), unless otherwise noted. Race and ethnic origins
 were self-reported. If baseline information was missing for some 
patients, the number of patients used in the denominator for percentage 
calculation was smaller than the total number of patients for the 
treatment group. Estimated glomerular filtration rate (eGFR) was 
calculated based on the Chronic Kidney Disease Epidemiology 
Collaboration equation based on serum creatinine or serum cystatin C.<a name="bbib17" href="#bib17" class="workspace-trigger">17</a>, <a name="bbib18" href="#bib18" class="workspace-trigger">18</a> UACR=urine albumin-to-creatinine ratio.</p>
<dl class="footnotes">
<dt id="tbl1fn1">*</dt>
<dd><p id="cenpara10">Chronic
 kidney disease stage 3 or higher at baseline. Concomitant 
antihypertensive use represents the modified intention-to-treat (mITT) 
population, therefore the denominators for percentage calculation are: 
183 for dulaglutide 1·5 mg, 180 for dulaglutide 0·75 mg, and 186 for 
insulin glargine.</p></dd>
</dl>
</div>